Barclays Analysts Give Clorox (NYSE:CLX) a $119.00 Price Target

Barclays set a $119.00 price objective on Clorox (NYSE:CLX) in a research note issued to investors on Tuesday morning, MarketBeat reports. The brokerage currently has an underweight rating on the stock.

Other analysts have also issued reports about the stock. Wells Fargo & Company reduced their price objective on shares of Clorox from $142.00 to $135.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 9th. Jefferies Financial Group reduced their price target on shares of Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. Citigroup lowered their price objective on shares of Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a research report on Monday, April 14th. UBS Group reduced their target price on Clorox from $176.00 to $154.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. Finally, Evercore ISI set a $140.00 target price on Clorox and gave the stock an “underperform” rating in a research report on Tuesday, May 6th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $145.17.

Clorox Price Performance

NYSE CLX opened at $129.53 on Tuesday. Clorox has a 1 year low of $117.35 and a 1 year high of $171.37. The business’s fifty day moving average is $127.49 and its two-hundred day moving average is $141.59. The stock has a market capitalization of $15.96 billion, a P/E ratio of 23.25, a P/E/G ratio of 3.14 and a beta of 0.51. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74.

Clorox (NYSE:CLX) last announced its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same period last year, the firm earned $1.71 earnings per share. The firm’s revenue for the quarter was down 8.0% on a year-over-year basis. On average, research analysts forecast that Clorox will post 7.15 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Pierre R. Breber acquired 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director owned 4,000 shares of the company’s stock, valued at approximately $546,280. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Clorox

A number of institutional investors have recently added to or reduced their stakes in CLX. Redwood Park Advisors LLC bought a new position in Clorox during the fourth quarter valued at about $26,000. American National Bank & Trust lifted its position in shares of Clorox by 69.5% in the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock worth $26,000 after acquiring an additional 89 shares during the period. Millstone Evans Group LLC bought a new position in Clorox in the fourth quarter worth $31,000. Wood Tarver Financial Group LLC acquired a new stake in shares of Clorox during the 4th quarter valued at about $31,000. Finally, GKV Capital Management Co. Inc. acquired a new stake in Clorox during the fourth quarter valued at approximately $32,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.